Re: ASCO and pharmacometrics
I agree with Phil. I have presented recently at two large endocrine meetings,
one in the US, one in Europe. In both cases, I took complicated PK/PD models
and kept it simple, emphasizing how the models could / would be used in
clinical development and clinical practice. The response at both meetings was
excellent — lots of people expressing interest in the models (and,
interestingly, two of the competitors to the company for which I was consulting
tried to enlist my consulting help).
And, I disagree with Nick’s comment yesterday. Perhaps oncology clinicians are
concerned about commas (I cannot speak to that issue) but I truly doubt Nick’s
claim that they don’t care about science — the advances in oncology in recent
years have been remarkable.
Dennis Fisher MD
P < (The "P Less Than" Company)
Phone: 1-866-PLessThan (1-866-753-7784)
Fax: 1-866-PLessThan (1-866-753-7784)
www.PLessThan.com http://www.plessthan.com/
Quoted reply history
> On Apr 7, 2016, at 7:49 AM, Lowe, Phil <[email protected]> wrote:
>
> I would echo Pascal’s point. Getting pharmacometric work into large clinical
> conferences is not straightforward. It can be done (see
> link) http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract
> http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract but note
> where I was in the author list as the sole modeller. It helps to work closely
> with the clinicians on the messaging. That said, it was fun at the meeting,
> explaining the data and model curves to clinicians with them asking how such
> knowledge could impact their patients. An eye-opener. Keep trying Naoto!
>
> All the best, Phil
>
> Philip J Lowe PhD
> Executive Director Pharmacometrics Scientist
> Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
> 4056 Basel, Switzerland
> Phone: +41 61 324 4676
> [email protected] <mailto:[email protected]>
>
> From: [email protected] <mailto:[email protected]>
> [mailto:[email protected] <mailto:[email protected]>]
> On Behalf Of Pascal Girard
> Sent: 06 April 2016 10:39
> To: Naoto Hayashi; [email protected] <mailto:[email protected]>
> Cc: nmusers
> Subject: RE: [NMusers] ASCO and pharmacometrics
>
> Dear Naoto,
>
> In the past, Rene Bruno got one poster accepted with discussion at ASCO. He
> is our ”champion” !
>
> I got one accepted on model for Exp-Tumor Size – OS at European Cancer
> Congress 2013 . But I can tell you that a medical writer rewrote it entirely
> and it took 1 month to get it reviewed and corrected by clinicians
> challenging every comma and p-value.
>
> To give you an idea of the respective size of the meetings: ACOP N=500, PAGE
> N>600, ECC N> 10,000, ASCO N>20,000.
>
> So the advice I would give, is just improve the quality and readability of
> our abstract and it will make it. By readability, I mean show it to an
> oncologist clinician. If he does not understand, rewrite it with the help of
> a medical writer …
>
> With best regards / Mit freundlichen Grüßen / Cordialement
>
> Pascal